19:25 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

Tasly, FDA discuss approval path for Chinese medicine product

FDA will require Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) to conduct an additional Phase III trial before it submits an NDA for Dantonic (T89), which could be the first traditional Chinese medicine to receive FDA approval...
21:00 , Aug 31, 2017 |  BC Extra  |  Company News

Tasly, FDA discuss approval path for Chinese medicine product

FDA will require Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) to conduct an additional Phase III trial before it submits an NDA for Dantonic (T89), which could be the first traditional Chinese medicine to receive FDA approval...
18:49 , May 12, 2017 |  BC Week In Review  |  Company News

Pharnext, Tasly forming drug combo JV

Pharnext S.A.S. (Euronext:ALPHA) and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) will form a JV to develop combination therapies integrating Tasly's traditional Chinese medicines and Pharnext's drug combination formulations, primarily in cardiovascular and oncology indications. Pharnext will...
23:07 , May 10, 2017 |  BC Extra  |  Company News

Pharnext, Tasly to form drug combo JV

Pharnext S.A.S. (Euronext:ALPHA) and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) will form a JV to develop combination therapies integrating Tasly's traditional Chinese medicines and Pharnext's drug combination formulations, primarily in cardiovascular and oncology indications. Pharnext will...